+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.

Age: 18Years - 80YearsAll GendersPhase 3
61 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of recombinant botulinum toxin type A Eveotox in adults with upper limb spasticity following stroke. This phase III clinical trial compares Eveotox to a placebo to observe its effects on muscle spasticity and related functional improvements. Participants will receive Eveotox in a double-blind manner during the first treatment cycle, followed by up to three open-label cycles of Eveotox. Those initially assigned to placebo will receive placebo only during the first cycle and then transition to up to three cycles of Eveotox. The study aims to closely monitor the treatments impact over these cycles. During the trial, participants will undergo assessments to evaluate spasticity and functional abilities using scales such as the Modified Ashworth Scale and Disability Assessment Scale. Safety and efficacy will be tracked within four weeks for primary outcomes and up to 52 weeks for secondary measures. Participants will be monitored throughout the study duration, which lasts until January 2028, including safety checks and evaluations of treatment response.

Age: 18Years - 80YearsAll GendersPhase 3
31 locations
P

Actively Recruiting

This research aims to evaluate the safety and effectiveness of TQA2225AP025, a recombinant human FGF21-Fc fusion protein, in adults with Non-Alcoholic Steatohepatitis NASH. It is a randomized, double-blind, placebo-controlled Phase II study designed to assess how well two different doses of this treatment work in managing NASH, a liver condition characterized by fat buildup and inflammation. Participants will receive either 25mg or 50mg of TQA2225AP025 or a matching placebo, given by weekly subcutaneous injections for 48 weeks. The study includes two experimental groups receiving the different doses, and all treatments are administered under blinded conditions to assess the treatment effects accurately. During the study, participants will undergo liver biopsies at the start and after 48 weeks to measure changes in liver condition using the NASH CRN scoring system. Safety will be closely monitored by tracking any adverse events throughout the treatment period. The study is expected to provide detailed information on both the treatment impact on liver health and its safety profile over nearly a year of participation.

Age: 18Years - 75YearsAll GendersPhase 2
53 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of an amino acid 15 peritoneal dialysis solution in patients undergoing peritoneal dialysis who have malnutrition. This Phase IV, multicenter, randomized, parallel controlled study focuses on patients receiving continuous ambulatory peritoneal dialysis CAPD maintenance treatment. The goal is to compare the amino acid solution with conventional glucose peritoneal dialysis solution in this population with End Stage Renal Disease ESRD. Participants are randomly assigned to one of two groups an experimental group receiving one bag of amino acid 15 peritoneal dialysate 2 liters each morning followed by conventional glucose dialysate, and a control group receiving conventional glucose peritoneal dialysis solution including 1.5% glucose dialysate 2 liters once daily. The number of dialysate exchanges, fluid volume, and dwell times are adjusted based on individual patient needs. The treatment period lasts 90 days, during which safety and effectiveness are monitored. Participants undergo screening, baseline assessments, and regular monitoring throughout the study. Blood tests and biochemical markers are checked at 30, 60, and 90 days, including serum albumin, transferrin, and prealbumin levels. Nutritional and physical assessments such as subjective global assessment SGA, arm muscle circumference AMC, mid-arm muscle circumference MAMC, body mass index BMI, and protein nitrogen appearance nPNA are evaluated at 90 days. The study also tracks total daily ultrafiltration volume and records all adverse events. The entire participation timeline includes a screening period before treatment and close observation during the 90-day treatment phase.

Age: 18Years - 75YearsAll GendersPhase 4
21 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying high school and college freshmen in Meishan City, Sichuan Province, China, who have strong positive tuberculosis TB skin tests indicating latent TB infection. The study evaluates whether taking a short-course preventive treatment can safely lower the risk of developing active TB over a 3 to 4-year period. This prospective, multi-center research integrates TB screening and preventive care into routine campus health services across 26 schools. Participants with strong positive skin tests and no active TB can voluntarily choose to start one of two World Health Organization-recommended 3-month preventive treatment regimens daily isoniazid plus rifampicin 3HR or twice-weekly isoniazid plus rifapentine 3H2P2. Treatment is supervised in campus clinics using a combination of in-person and smartphone video directly observed therapy. Those who opt not to take medication receive routine health observation without preventive treatment. During the study, researchers monitor participants for 3 to 4 years to track who develops active TB and to assess treatment safety, including adverse events like liver toxicity. Participants undergo baseline symptom screening, chest x-rays, and skin testing. Data analysis uses advanced methods to address non-random treatment assignment. The primary outcome is the occurrence of active tuberculosis up to four years after initial screening from the time latent TB infection eligibility is confirmed.

Age: 14Years - 24YearsAll GendersPhase 4
2 locations
N

Actively Recruiting

Researchers are evaluating a new neoadjuvant treatment approach for patients with resectable stage IB to IIIB non-small cell lung cancer NSCLC. This prospective Phase II study aims to assess the effectiveness and safety of combining CT-guided Cryo-Thermal Ablation with toripalimab and platinum-based doublet chemotherapy before surgery. The study focuses on improving major pathological response rates since many patients currently do not achieve a complete response with chemoimmunotherapy alone. Participants will first undergo a CT-guided Cryo-Thermal Ablation procedure targeting the primary lung tumor. After that, they will receive three planned cycles of toripalimab, an anti-PD-1 monoclonal antibody, combined with platinum-based doublet chemotherapy administered every three weeks. Following these treatments, patients will have a preoperative reassessment before undergoing curative-intent surgical removal of the tumor. The study includes about 40 participants and is conducted across multiple centers. During the trial, participants will be closely monitored through pathological evaluations of surgical specimens, imaging assessments, and health-related quality of life questionnaires. Researchers will measure outcomes such as pathological complete response rate, major pathological response rate, objective response rate, event-free survival, overall survival, and treatment-emergent adverse events. Additional exploratory analyses will examine immune responses and molecular changes using advanced genomic and proteomic techniques. The total follow-up period may extend up to approximately five years to assess long-term outcomes.

Age: 18Years - 80YearsAll GendersPhase 2
9 locations